Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLANZAPINE Cause Malignant neoplasm progression? 35 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Malignant neoplasm progression have been filed in association with OLANZAPINE (Olanzapine). This represents 0.1% of all adverse event reports for OLANZAPINE.

35
Reports of Malignant neoplasm progression with OLANZAPINE
0.1%
of all OLANZAPINE reports
27
Deaths
25
Hospitalizations

How Dangerous Is Malignant neoplasm progression From OLANZAPINE?

Of the 35 reports, 27 (77.1%) resulted in death, 25 (71.4%) required hospitalization, and 3 (8.6%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLANZAPINE. However, 35 reports have been filed with the FAERS database.

What Other Side Effects Does OLANZAPINE Cause?

Drug ineffective (5,139) Weight increased (3,588) Off label use (3,256) Toxicity to various agents (3,175) Somnolence (2,612) Sedation (2,130) Suicide attempt (2,116) Confusional state (1,898) Condition aggravated (1,810) Overdose (1,765)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which OLANZAPINE Alternatives Have Lower Malignant neoplasm progression Risk?

OLANZAPINE vs OLANZAPINE\SAMIDORPHAN L-MALATE OLANZAPINE vs OLAPARIB OLANZAPINE vs OLARATUMAB OLANZAPINE vs OLECLUMAB OLANZAPINE vs OLIVE OIL\SOYBEAN OIL

Related Pages

OLANZAPINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression OLANZAPINE Demographics